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ABSTRACT
The study of proteins is central to unraveling (patho)physiological processes and 
has contributed greatly to our understanding of biological systems. Corresponding 
studies often employ procedures to enrich proteins from their biological matrix 
using antibodies or other affinity binders coupled to beads with a large surface area 
and a correspondingly high binding capacity. Striving for maximal binding capacity 
may, however,  not always be required or desirable,  for example for proteins of 
low abundance. Here we describe a simplified immunoprecipitation in 96-well ELISA 
format (IPE) approach for fast and easy enrichment of proteins. The applicability 
of this approach for enriching low-abundant proteins was demonstrated by an 
IPE-based quantitative workflow using liquid chromatography-mass spectrometry 
(LC-MS) for the soluble Receptor of Advanced Glycation End-products (sRAGE), 
a promising biomarker in chronic obstructive pulmonary disease (COPD). The 
method was validated according to U.S. Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) guidelines and enabled accurate quantitation of 
sRAGE between 0.1 and 10 ng/mL in 50 µL serum. The assay showed substantial 
correlation with the two most commonly-used sRAGE immunoassays (ELISAs) (R2-
values between 0.7 and 0.8). However, the LC-MS method reported 2 to 4 times 
higher sRAGE levels compared to the ELISAs, which is largely due to a suboptimal 
amount of capturing antibody and/or calibration strategy used by the immunoassays. 
In conclusion, our simplified IPE approach proved to be an efficient strategy for 
enriching the low-abundant protein sRAGE from serum and may provide an easy to 
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3.1.  INTRODUCTION
Studying proteins in complex, biological matrices is a common feature of (bio)medical research 
and has contributed considerably to our current understanding of life processes. For studies 
on protein expression, structure, and interactions, a variety of analytical techniques is being 
deployed including gel electrophoresis, liquid chromatography and mass spectrometry, which 
may all require specific protein enrichment procedures depending on the aim of a study and/
or the protein(s) of interest.1,2 Immunopurification is an eminent example of such enrichment 
techniques and uses specific ‘bait’ proteins to selectively bind and purify the targets of interest 
(e.g. antigens).3 Antibodies are generally used to capture proteins or even protein complexes, 
though conversely, antigens may also serve as baits to capture antibodies which may be valuable 
for analyzing autoantibodies.4,5 The former approach is a widely-used application of antibodies 
in basic and applied scientific research, and has contributed to the conception of antibodies 
being the ‘workhorses’ of (bio)medical experiments.6
Besides bait proteins, immunopurification strategies require a (solid) support to which a 
bait protein is or can be coupled thereby allowing to separate the bait/target-complex from the 
original matrix.7 Examples of such supports comprise gel-based (e.g. agarose) and magnetic 
beads each having specific advantages and disadvantages in terms of binding capacity, protocol 
flexibility and throughput as well as the degree and extent of non-specific binding.8 As alternative 
to bead-based supports, (adsorptive) microtiter plates commonly used for immunoassays, have 
also been employed for immunoaffinity enrichment purposes.9-12 Some hybrid assays based on 
immunoaffinity enrichment and digestion in microtiter plates followed by LC-MS detection 
demonstrated efficient enrichment of low abundant proteins.9,10 A similar approach (referred 
to as immunoprecipitation in 96-well ELISA format, or IPE ) showed matching capabilities, 
though IPE features a decoupled enrichment and digestion strategy and thereby also allows 
to study intact proteins, for example by top-down proteomics or Western Blot analysis.11 This 
approach utilizes microtiter plates coated with Protein (A/)G to which antibodies are bound 
and covalently coupled with disuccinimidyl suberate (DSS). Although this methodology has 
many potential applications, examples of such applications are absent in literature, which 
may be because IPE’s advantages compared to (magnetic) beads-based alternatives are less 
pronounced due to its dependence on Protein (A/)G-coated plates. 
 The soluble Receptor of Advanced Glycation End-products (sRAGE) is a potential 
biomarker for chronic obstructive pulmonary disease (COPD) and an example of a clinically 
relevant protein of low abundance.13 sRAGE is formed after proteolytic cleavage of membrane-
bound RAGE, a pattern recognition receptor involved in pro-inflammatory signaling 
pathways.14 In addition, sRAGE can be formed upon alternative splicing of the AGER gene 
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thereby leading to a RAGE splice variant known as endogenous secretory RAGE (esRAGE).15 
Circulating RAGE has anti-inflammatory properties by acting as a decoy receptor for pro-
inflammatory RAGE ligands and also by inhibiting homo-dimerization of membrane-bound 
RAGE which is presumed to be essential for RAGE activation.16-18 In several (large-scale) 
biomarker studies, sRAGE was put forward as useful biomarker in COPD, particularly 
with respect to the presence and progression of emphysema, and sRAGE was consequently 
considered for biomarker qualification by the U.S. Food and Drug Administration (FDA).19,20 
However, current knowledge about sRAGE is strongly depending on measurements with 
“research-grade” enzyme-linked immunosorbent assays (ELISA) from a single vendor, and 
appropriately validated assays are lacking.19 Furthermore, it is known that sRAGE is regulated 
by alternative splicing and post translational modifications, including proteolytic cleavage and 
N-linked glycosylation.21 Circulating RAGE thus likely comprises a series of related proteins 
(also referred to as ‘protein species’ or ‘proteoforms’) with potentially different functions, 
activities or ligand specificities.21-23 It is therefore not only essential that sRAGE assays for 
clinical use are adequately validated, but these assays also need to be adequately characterized 
with respect to the exact forms of circulating RAGE that are being quantified.
 In this study, we present an efficient, fast, and easy to use enrichment strategy for proteins 
in complex matrices on the basis of antibodies directly immobilized on high affinity microtiter 
plates. This methodology was combined with liquid chromatography-mass spectrometry (LC-
MS) for quantifying sRAGE in human serum based on specific peptides in its N-terminal 
region which is essential for the binding of most RAGE ligands.14,24 The method was validated 
according to FDA and European Medicines Agency (EMA) guidelines with a lower limit of 
quantification (LLOQ) of 0.1 ng/mL.25,26 The validated LC-MS assay for sRAGE is expected 
to contribute to the development of sRAGE as biomarker in COPD. 
3.2.  EXPERIMENTAL SECTION
3.2.1.  Chemicals and materials 
Recombinant human RAGE encompassing the extracellular domain of this protein (Cat. 
No. C423; UniProtKB ID ‘Q15109’; Ala23-Ala344 with C-terminal hexa-histidine tag) was 
purchased from Novoprotein (Summit, NJ, U.S.A.), monoclonal anti-RAGE antibody (Cat. 
No. MAB11451; clone 176902) was obtained from R&D Systems (Abingdon, U.K.), and 
stable-isotope-labeled RAGE peptides (i.e. IGEPLVLK* & VLSPQGGGPWDSVAR*) were 
synthesized by Pepscan Presto (Lelystad, The Netherlands). Acetonitrile (ACN; LC-MS grade) 
was obtained from Biosolve (Valkenswaard, The Netherlands) and sequencing grade modified 
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96 wells plates with MaxiSorp™ coating (Cat. No. M9410), bovine serum albumin (BSA; Cat. 
No. A7638), and phosphate buffered saline (PBS; 10x; Cat. No. D1408) as well as all other 
chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands).
3.2.2.  Serum samples
Serum was obtained from healthy volunteers and was pooled for preparation of the quality 
control (QC-)samples. Pooled serum was used directly as QC-medium sample, diluted 
eight times with 1% BSA in 1x PBS, pH 7.4 (Surrogate Matrix) for preparation of the QC-
low sample, or fortified with 5 ng/mL recombinant RAGE to obtain the QC-high sample. 
Recovery and spike recovery experiments were carried out using six different sources of human 
serum from healthy subjects (all from Seralab). Spike recovery experiments were furthermore 
performed on a lipemic serum sample (triglyceride content >150 mg/dL; obtained from 
Seralab) and a hemolytic sample which was prepared by adding freeze-thawed whole blood 
(2%) to human serum. 
3.2.3.  Calibrants and internal standard. 
Lyophilized RAGE was dissolved in Milli-Q water to obtain a 200 µg/mL solution (based on 
the quantity as declared by the supplier) which was diluted to 100 µg/mL with 1´ PBS, pH 
7.4 (PBS Buffer) after checking protein purity by SDS-PAGE and MALDI-TOF MS, which 
did not reveal the presence of proteins other than sRAGE. The resulting stock solution was 
sequentially diluted to 100 ng/mL with Surrogate Matrix (see Serum samples section above), 
and calibration samples were prepared at 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 8.0 and 10.0 ng/mL. For 
the internal standard (IS), SIL-peptides (supplied as 5 pmol/µL solutions in 5% ACN) were 
mixed 1:1 and diluted to 5 fmol/µL with 1% dimethyl sulfoxide (DMSO) in water.
3.2.4.  Simplified IPE protocol
(1: plate coating) The plate was coated using 100 µL aliquots of PBS Buffer containing 
0.5 µg of antibody (from a 200 µg/mL stock solution; antibody was reconstituted in PBS 
Buffer) which were added to microplate wells, followed by overnight incubation at room 
temperature. (2: plate blocking) After removal of unbound antibody by three washing steps 
with 300 µL Wash Buffer (0.05% Tween-20 in PBS Buffer), uncoated surface was blocked 
with 300 µL Surrogate Matrix for 60 minutes while shaking on a plate shaker (600 RPM; 
room temperature). (3: immunocapture) Wells were washed three times with 300 µL Wash 
Buffer, and 100 µL of Sample Solution (for which 60 µL of serum was pre-mixed with 60 µL 
Surrogate Matrix to allow quantitative transfer of Sample Solution) was added to the wells 
for the immunocapture of sRAGE (120 min; 600 RPM; room temperature). (4: analyte 
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collection) The wells were washed three times with 300 µL Wash Buffer, and sRAGE was 
eluted from the antibodies with 100 µL 0.1% aqueous trifluoroacetic acid (TFA) solution 
(10 min; 600 RPM; room temperature). The IPE eluate was collected in low binding tubes 
(Eppendorf; Cat. No. 022431081) using low binding tips (VWR; Cat. No. 613-0891), and 
the samples were dried in a vacuum centrifuge at 60 ºC. 
3.2.5.  In-solution digestion
Proteins were reconstituted in 50 µL Digestion Buffer (100 fmol/mL SIL-peptides in 50 mM 
ammonium bicarbonate (ABC)). Subsequently, disulfide bonds were reduced with 10 mM 
dithiothreitol (DTT) (5 µL 110 mM DTT in 50 mM ABC) for 30 minutes (60 ºC; 600 
RPM), and thiols were alkylated with 20 mM iodoacetamide (IAM) (5 µL 240 mM IAM in 
50 mM ABC) for 30 minutes in the dark (room temperature). After quenching the excess of 
IAM with a 0.5 molar excess of DTT (6 µL 110 mM DTT in 50 mM ABC), 100 ng trypsin 
was added to each sample, and proteins were digested by overnight incubation (37 °C; 600 
RPM). The IPE digests were acidified by adding 2 µL of 50% formic acid (FA), and 15 µL of 
sample was analyzed by LC-MS. 
3.2.6.  LC-MS
Analyses were performed with a Waters Ionkey/MS system using an ACQUITY M-Class 
UPLC and a XEVO TQ-S mass spectrometer (Milford, MA, U.S.A.). Chromatographic 
separation was achieved on a C18-bonded Waters iKey HSS T3 Separation Device (1.8 μm 
particles, 100 Å pore size, 150 μm × 100 mm; Cat. No. 186007261) which was kept at 40 °C, 
using 0.1% FA in H2O as mobile phase A and 0.1% FA in ACN as mobile phase B. Samples 
were loaded onto a Dionex Acclaim PepMap100 C18 trap column (5 μm particles, 100 Å pore 
size, 300 μm × 5 mm; Cat. No. 160454) for 2.5 min with 3% B at 20 µL/min. Subsequently, 
peptides were separated on the analytical column at 3 µL/min with a 10 minute linear gradient 
from 3 to 33% B, after which the column was cleaned (0.6 min at 60% B and 2.1 min at 95% 
B) and equilibrated (4.3 min at 3% B). Mass spectrometric detection was performed using the 
following conditions: ESI positive, capillary voltage 3.5 kV, cone voltage 30 V, source offset 
50 V, source temperature 120 °C, cone gas (nitrogen) flow 150 L/h, sheath (nanoflow) gas 
(nitrogen) flow 0.2 Bar, and collision gas (argon) flow 0.15 mL/min. MRM transitions and 
settings for IGEPLVLK (selected for quantification) and VLSPQGGGPWDSVAR (selected 
for confirmation) are presented in Table S-1 (Supporting Information). The Ionkey/MS system 
was operated under the Waters MassLynx software suite (version 4.1), and the TargetLynx 
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3.2.7.  Method validation
The method was validated according to FDA and EMA guidelines, and the following criteria 
were addressed: selectivity (e.g. spike recovery and ligand challenge tests), accuracy & precision, 
recovery, calibration curve, and stability (e.g. 13 days benchtop, 10× freeze-thaw, 4 months -20 
°C & -80 °C storage, 28 days autosampler (10 °C), and 443 days stock stability).25,26 For the 
recovery experiment, 10 µL 50 ng/mL sRAGE was added to 240 µL serum (addition of 2 
ng/mL sRAGE; < 5% non-matrix solution in the final sample) to obtain the pre-IPE spiked 
samples, and 10 µL 10 ng/mL sRAGE was added to IPE eluates (addition of 2 ng/mL) to 
obtain the post-IPE spiked samples. The sRAGE dilutions for this experiment were prepared in 
50 mM ABC since adding Surrogate Matrix to the IPE eluates would introduce excessive BSA 
to the samples thereby interfering with digestion and LC-MS analysis. sRAGE in Surrogate 
Matrix was used for the spike-recovery experiments, and the corresponding spiking procedure 
was similar to that of the pre-IPE spiked samples of the recovery experiment. Ligand challenge 
tests were performed by adding 200 ng of fully-reduced HMGB1 (HMGBiotech, Milano, 
Italy; Cat. No. HM-116), S100A12 (Novoprotein; Cat. No. C743), serum amyloid A1 (SAA1; 
Novoprotein; Cat. No. C633), Nε-(carboxymethyl)lysine-modified bovine serum albumin 
(CML-BSA; Academy Bio-Medical Co., Houston, TX, U.S.A.; Cat. No. 30P-CML-BS102), 
or by adding 5% cigarette smoke extract (the first-hand smoke of two research cigarettes with 
filters cut off (University of Kentucky, Lexington, KY, U.S.A.; Cat. No. 3R4F) was pumped 
through 25 mL of RMPI-1640 medium using a peristaltic pump to obtain a 100% CSE 
solution) to the samples, or through addition of 5% A549 human alveolar epithelial cell lysate 
(10,000,000 cells/mL in RMPI-1640 medium which were lysed by 30 seconds of sonication 
using a probe sonicator followed by centrifugation for 5 min at 1,000 × g to pellet debris). For 
recovery and selectivity experiments, samples were incubated for at least 30 minutes following 
addition of sRAGE or the ligands prior to initiating sRAGE immunocapture.
3.2.8.  Method comparison
For method comparison, 40 serum samples were analyzed from a cross-sectional study 
(NCT00807469) within the University Medical Center Groningen (UMCG).27 For this 
study, ethical approval has been granted by the UMCG’s review board (METc 2008/136), 
and the study adheres to the Declaration of Helsinki. Blood samples were collected in plastic 
coagulation tubes (Becton Dickinson), which were incubated for at least 30 minutes at room 
temperature prior to centrifugation at 1,000 x g and 4 °C for 10 minutes. After collecting the 
serum fraction, samples were aliquoted into 1.4 mL polypropylene storage tubes (Thermo 
Fisher, Cat. No. 3712), and stored at -80 °C until further analysis. In all 40 samples, sRAGE 
52 
|  CHAPTER III
was quantified by LC-MS as well as with the R&D Systems Human RAGE DuoSet (Cat. 
No. DY1145) and Quantikine (Cat. No. DRG00) ELISA kits, both performed according to 
manufacturer’s instructions.
3.3.  RESULTS AND DISCUSSION
3.3.1.  Development of the simplified immunoprecipitation in 96-well ELISA 
format (IPE) approach for sRAGE in serum
As serum sRAGE levels are reported to be in the low to sub ng/mL range, enrichment of 
sRAGE prior to LC-MS analysis is required.16 For this purpose, we adopted a strategy which 
builds upon the widely-used microtiter plate-based format that forms the basis of most 
immunoassays. Our strategy furthermore represents a simplified version of the previously 
described immunoprecipitation in 96-well ELISA format (IPE)11 for which we particularly 
aimed to circumvent the need to use Protein (A/)G coated plates (comparable with previously 
published approaches9,10) as non-occupied Protein (A/)G residues may favor non-specific 
binding and thus may lead to increased background signals.28 Accordingly, the resulting 
approach initially follows the typical steps of an ELISA, but instead of adding a secondary 
antibody for signal amplification and detection, enriched proteins are eluted from the capturing 
antibody. Proteins can subsequently be studied in their intact form by mass spectrometry and 
Western Blot analysis, or can be digested with a protease (e.g. trypsin) and analyzed by LC-MS, 
which was the selected strategy for our sRAGE assay. Optimization of the amount of antibody 
per sample (see Figure S-1) revealed that less than 0.5 µg of antibody was needed to detect 
sRAGE at clinically relevant levels with sensitivity down to 0.1 ng/mL (see Figure 1). The 
required amount of antibody obviously depends greatly on the dissociation constant (Kd) and 
quality of an antibody28, yet 0.25 to 0.5 µg of antibody per sample corresponds well with the 
amounts that are generally used for immunoassays and is furthermore eight to twenty times 
lower than the amounts that were previously used in IPE protocols.11
3.3.2. Selection of internal standard and calibration matrix
Stable-isotope-labeled (SIL) versions of authentic analytes are the internal standards of 
choice to enable adequate correction for variability arising from sample preparation or LC-
MS, particularly when an immunopurification step is included for analyte enrichment.29,30 
Unfortunately, such standards are often not available (in sufficient quality) for intact proteins, 
as is the case for sRAGE. Consequently, SIL versions of selected proteotypic peptides were 
employed as internal standards which were added to the samples after the IPE procedure. To 
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during method validation revealing a consistently high and precise recovery of sRAGE using 
the IPE protocol (see the Assay characteristics section below).
Figure 1. Selected Ion Chromatograms of the sRAGE-derived proteotypic peptides (A) IGEPLVLK and (B) 
VLSPQGGGPWDSVAR at 0.1 ng/mL in Surrogate Matrix (1% BSA in 1× PBS, pH 7.4). 
 For selection of proteotypic peptides, Skyline software (version 3.5.0.9319; UniProtKB 
reference proteome: ‘UP000005640 canonical + isoforms’) and the online MRM Peptide 
Picking Tool (version 1.0; UniProtKB entry: ‘Q15109’) were employed.31,32 Trypsin was 
selected as protease, and peptides were evaluated on the basis of their uniqueness, presence 
in the mature protein, presence in relevant isoforms (e.g. esRAGE), peptide length, absence 
of post translational modification (PTM) sites (e.g. N-linked glycosylation), and location 
close to or, preferably, within the N-terminal domain of sRAGE which is most relevant for 
ligand binding.14,24 In addition, genetic variation was considered by consulting the ExAC 
Browser (version 0.3; Ensembl gene: ‘ENSG00000204305’) and peptides encompassing 
highly prevalent SNP-sites (e.g. rs2070600 SNP leading to the Gly82Ser substitution) were 
excluded.33 Upon in silico evaluation of proteotypic peptides as well as empirical assessment of 
their ESI-ionization properties, the following two peptides were selected for further method 
development: r.IGEPLVLK.c (30-37) and k.VLSPQGGGPWDSVAR.v (63-77). Since 
the IGEPLVLK peptide performed best in terms of accuracy and precision during method 
validation, this peptide was selected for sRAGE quantification (quantifier peptide), whereas 
the VLSPQGGGPWDSVAR peptide was used to confirm the presence of sRAGE (qualifier 
peptide).
With respect to selection of the calibration matrix, employing an authentic matrix for 
preparation of the calibration samples would be preferable, yet an analyte-free, authentic matrix 
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could not be obtained.29 Accordingly, several surrogate matrices were evaluated including 
complex matrices (e.g. fetal calf serum) as well as a simple, artificial matrix consisting of 1% 
BSA in PBS. The recovery of spiked (recombinant human) sRAGE from these matrices was 
comparable to that of spiked sRAGE from human serum (see Figure S-2). Therefore, 1% BSA 
in PBS was selected as surrogate matrix and its suitability was demonstrated during method 
validation (see the Assay characteristics section below).
3.3.3.  Assay characteristics
A concise summary of the validation results is presented in Table 1 while a full overview is 
given in Tables S-2 to S-19 (Supporting Information). Accurate quantification of sRAGE was 
demonstrated for a 1/x weighted linear calibration model using 8 non-zero standards between 
0.1 ng/mL (LLOQ: CV & bias ± 10%) and 10 ng/mL. Evaluation of accuracy and precision 
revealed comparable biases and CVs for all three QC-levels (approximately ±5% and 10%, 
respectively) suggesting that methodological variation due to the IPE procedure (for which an 
internal standard to compensate for methodological variability is absent) is constant for low, 
midrange, and high sRAGE levels and within the approved limits for regulated bioanalysis. 
The extent of the IPE recovery was consistently high ranging from 81 to 84% and precise (CVs 
of 6-7%) regardless of whether the average of duplicate measurements or individual replicates 
were considered. Accordingly, these data justify quantifying sRAGE by single measurements 
which entails that LC-MS analysis of samples from one 96-well microtiter plate (i.e. 81 clinical 
samples, 9 calibrants, and 6 QC-samples) can be performed within two days.
 Sample stability was assessed under conditions going beyond what is relevant for typical 
clinical assays after 13 days of storage on the benchtop (room temperature), 4 months of 
storage in the freezer (-20 °C and -80 °C), and upon 10 freeze-thaw cycles. These stability 
assessments indicated that sRAGE is a rather stable biomarker with respect to IPE enrichment 
and the proteotypic peptide that is used for sRAGE quantification by LC-MS.
 Selectivity of the sRAGE method was studied by spike-recovery and ligand challenge 
testing. Spike-recovery experiments were carried out using six different sources of serum which 
were processed in duplicate. The observed biases were within ± 15% when either the average 
sRAGE level of both replicates or the levels of the individual replicates were assessed. With 
respect to these data, it should be noted that one of the samples (subject ♂3, see Table S-17) 
contributed mostly to the observed (negative) bias. The reason for this difference is currently 
unclear. Even though the overall bias is within acceptable limits, this observation indicates 
that employing a whole-protein SIL internal standard should be considered as relevant future 
enhancement for our assay. Moreover, spike-recovery assessment was extended to a hemolytic 
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Table 1. Summary of validation data.a
QC-low QC-medium QC-high
CV biasb CV biasb CV biasb
accuracy & precision 
(3 runs, in 6-fold)
run 1 12% -5% 11% 1% 4% 1%
run 2 10% 1% 5% 7% 6% 4%
run 3 8% 4% 14% -8% 11% -5%
autosampler stability 10 °C 
(28 days, in 3-fold) 1% 2% 1% -4%
bench-top stability room temperature 
(13 days, in 3-fold) 6% 2% 1% 5%
freeze-thaw stability -20 °C 
(10 cycles, in 3-fold) 7% 0% 12% -8%
storage stability -20 °C 
(4 months, in 3-fold) 11% -7% 2% -2%
storage stability -80 °C 




stock stability -20 °C (443 days, in 5-fold) 3% 1%
replicate 1 replicate 2 average of replicates
recovery CV recovery CV recovery CV
recovery 
(6 different serum samples, in 1- or 2-fold) 81% 6% 84% 7% 83% 6%
replicate 1 replicate 2 average of replicates
bias bias bias
spike recovery 
(6 different serum samples, in 1- or 2-fold) -10% -13% -12%
lipemic sample spike recovery 
(in 2-fold) -13%






CV bias CV bias
HMGB1 challenge 
(4 µg/mL, in 5-fold) 6% 10%
CML-BSA challenge 
(4 µg/mL, in 5-fold) 12% 4%
S100A12 challenge 
(4 µg/mL, in 5-fold) 4% 12%
CSE challenge 
(5%, in 5-fold) 6% -8%
SAA1 challenge 
(4 µg/mL, in 5-fold) 9% 7%
Cell lysate challenge 
(5%, in 5-fold) 6% -1%
a An extensive summary of the validation results is presented in Tables S-2 to S-19 (Supporting Information). 
b The average value of measured concentrations during the precision and accuracy experiments was used as nominal 
concentration
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interfering ligands, we selected high mobility group box 1 protein (HMGB1) which is the most 
studied and characterized RAGE ligand21,34, S100 calcium-binding protein A12 (S100A12) 
and serum amyloid A1 (SAA1) as examples of damage-associated molecular pattern (DAMP) 
proteins known to bind RAGE35,36, and Nε-(carboxymethyl)lysine-modified bovine serum 
albumin (CML-BSA) was included as a surrogate for advanced glycation end-product-modified 
proteins.17 All ligands were added at 4 µg/mL (>10,000-times molar excess). Furthermore, we 
aimed to mimic potential interferences arising from cigarette smoking by challenging samples 
with cigarette smoke extract (CSE) in view of future studies on COPD patients. Since many 
RAGE ligands are DAMPs which are released upon cigarette smoke-induced cell death, we 
also studied potential interferences by challenging samples with lysed human alveolar epithelial 
A549 cells.37,38 Ultimately, none of the tested ligands affected the measured sRAGE levels, as 
reported previously for the Quantikine sRAGE ELISA as well.39 
3.3.4.  Method comparison
Agreement between the LC-MS sRAGE assay and two widely-used sRAGE immunoassays 
(i.e. R&D Systems DuoSet and Quantikine ELISAs for RAGE) was assessed on the basis 
of 40 clinical samples using linear regression and Bland-Altman plots (see Figure 2). These 
comparisons revealed substantial correlations between the LC-MS assay and the DuoSet and 
Quantikine ELISAs with coefficients of determination of 0.72 and 0.79, respectively, as well 
as substantial correlation between the immunoassays (R2 = 0.80). However, sRAGE levels 
obtained with the ELISAs were considerably lower than those obtained by the LC-MS assay 
with average relative differences of -84% and -131% (2.0 and 3.9 times lower sRAGE levels) 
for the Quantikine and DuoSet ELISAs, respectively. 
Possible explanations for the observed differences in sRAGE levels obtained by the assays 
include different specificities for the antibodies used in the assays (information on the epitopes 
is not available), incomplete capture of sRAGE from serum due to an insufficient amount of 
primary antibody in the immunoassays as well as differences between the declared and the 
actual protein quantities of the sRAGE stocks used for preparation of the calibration curves. The 
latter two explanations were investigated by increasing the amount of antibody for the DuoSet 
ELISA whose design is rather flexible thereby allowing to deviate from recommended protocol, 
from 0.1 µg (manufacturer’s recommendation; this amount was actually insufficient for the 
IPE method, see Figure S-1) to 0.5 µg per sample (i.e. the amount used for IPE). Furthermore, 
the DuoSet sRAGE standard was quantified using the LC-MS assay, and ELISA data were 
corrected for the observed difference between the expected and the actual sRAGE concentrations 
(4.0 and 2.9 ng/mL, respectively) as measured by LC-MS. Upon increasing the amount of 
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yielding sRAGE levels comparable with those obtained by the LC-MS assay for the QC-low 
sample, albeit to a lesser extent for the QC-medium and QC-high samples. Referencing the 
ELISA protein stock against that of the LC-MS assay, however, led to a downward adjustment 
of the sRAGE levels determined by ELISA (see ‘0.1 µg corr.’ and ‘0.5 µg corr.’ in Figure 3). 
Increasing the amount of capturing antibody in the ELISA was thus the most important factor 
to bring the results more in line with the IPE assay. However, it is conceivable that optimizing 
the calibration strategy of the ELISA, for example by employing a surrogate matrix which 
better resembles the complexity and composition of serum than the surrogate matrix used for 
the ELISA (i.e. 1% BSA in PBS), furthermore represents a strategy to improve the accuracy of 
this particular assay. 
Figure 3. sRAGE levels for the (A) QC-low, (B) QC-medium, and (C) QC-high samples as measured by the 
DuoSet ELISA using 0.1 µg (manufacturer’s recommendation; N = 2) and 0.5 µg of capturing antibody per 
well (N = 2), and also as measured by IPE LC-MS (nominal sRAGE levels as determined during validation). 
ELISA calibration was performed with the supplied sRAGE protein standard either using the protein quantity 
as declared by the manufacturer (‘0.1 µg’ and ‘0.5 µg’) or by using the corrected protein quantity upon 
referencing the ELISA protein standard against the protein standard of the LC-MS method (‘0.1 µg corr.’ and 
‘0.5 µg corr.’).
The remaining bias may be the result of the different detection principles of both assay 
platforms. Whereas readouts of an ELISA are indirect and rely on the ability of a detection 
antibody to bind the target molecule in order to generate a signal, LC-MS-based approaches 
analyze the target molecule based on protein-specific peptides. This readout is thus based on 
confined chemical information which in case of our method relates to whether a circulating 
RAGE molecule (enriched by IPE) contains the IGEPLVLK sequence. Considering this 
principle, a form of RAGE lacking the N-terminal domain which is essential for binding 
of RAGE to most of its ligands, will not be picked up by the MS-based assay, as both the 
quantifier and qualifier peptides are located in the N-terminal domain.14,24 Furthermore, the 
MS-based method does not discriminate between circulating RAGE formed upon shedding of 
membrane-bound RAGE by metalloproteases and esRAGE which is produced by alternative 
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Thus, results obtained with the different assay platforms are prone to be different due to the 
distinct detection principles of both platforms and the expected heterogeneity of circulating 
RAGE molecules.
3.3.5.  Perspectives for the IPE assay
The IPE approach is easy to set up and use, antibody efficient, and a robust strategy for 
enriching low-abundant proteins like sRAGE from highly complex biological samples such as 
serum. It is conceivable that this assay format can be applied to other low-abundant proteins 
in other biological matrices and possibly also for studying protein-protein interactions or with 
the purpose of finding missing proteins (of low abundance).40,41 In fact, the IPE principle is 
currently being investigated for pull-down assays of low-abundant, intracellular proteins with 
encouraging results (data not shown). With respect to future applications, it should however be 
noted that the IPE Wash Buffer contains Tween-20 which proved to be necessary for recovery of 
sRAGE, but which may interfere with LC-MS analyses. In our case, Tween-20 did not present 
difficulties, and remaining detergent in the LC system was removed by regularly flushing the 
LC flow paths with high percentages of eluent B. This may not be possible for some other 
applications, and washing conditions may need to be optimized accordingly. Moreover, the 
use of surfactants that can be removed more easily or that are more compatible with ESI-MS 
comprises another area that needs to be investigated.  
3.4.  CONCLUSIONS
The simplified immunoprecipitation in 96-well ELISA format (IPE) methodology is an easy 
and efficient platform for immunoaffinity enrichment. Its potential for enriching proteins 
from complex matrices was demonstrated in a mass spectrometry-based workflow to quantify 
the low-abundant biomarker sRAGE in human serum. The method was validated according to 
U.S. Food and Drug Administration and European Medicines Agency guidelines and enabled 
quantification of sRAGE in human serum at clinically relevant levels (between 0.1 and 10 
ng/mL). Comparison of this assay with the two most widely-used sRAGE ELISAs revealed 
substantial correlation between all three assays; however, IPE LC-MS reported 2 to 4 times 
higher sRAGE levels compared to the ELISAs. This discrepancy can largely be explained by an 
insufficient amount of capturing antibody per well used by the ELISAs to capture all sRAGE 
in serum samples, though an improper calibration strategy of the ELISA and the different 
detection principles of both assay platforms may provide partial explanations as well. In 
conclusion, the IPE format allows to efficiently establish immunoaffinity enrichment strategies 
which may simplify and foster the study of proteins in complex matrices.
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3.6.  SUPPORTING INFORMATION
The Tables S-2 to S-19 can be found in the online version of the Supporting Information which 
is available on the ScienceDirect Publications website at DOI: 10.1016/j.talanta.2018.02.015.
Figure S-1. Results of the IPE antibody titration experiments using (A) QC-low and (B) QC-high samples 
(displayed as mean sRAGE levels plus standard deviation; N = 2).
Figure S-2. Evaluation of sRAGE recovery from human serum (endogenous sRAGE level ± 1.5 ng/mL), 1% 
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Figure S-3. Comparisons between the individual replicates (replicate 1 = black & replicate 2 = grey) as 
measured by the quantitative IPE LC-MS sRAGE method and the R&D Systems Human RAGE DuoSet and 
Quantikine ELISAs using (A) linear regression and (B) Bland-Altman plots.
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Table S-1. MRM transitions and settings for the proteotypic sRAGE peptides and their SIL versions.







IGEPLVLK 434.79 - [M+2H]2+ 755.47 - y71+ 0.05 45 16
569.40 - y51+ 0.05 45 16
698.44 - y61+ 0.05 45 14
IGEPLVL[K]a 438.79 - [M+2H]2+ 763.48 - y71+ 0.05 45 16
577.42 - y51+ 0.05 45 16
706.46 - y61+ 0.05 45 14
VLSPQGGGPWDSVAR 763.39 - [M+2H]2+ 613.80 - y122+ 0.05 60 24
657.32 - y132+ 0.05 60 24
1001.48 - y101+ 0.05 60 32
VLSPQGGGPWDSVA[R]a 768.40 - [M+2H]2+ 618.80 - y122+ 0.05 60 24
662.32 - y132+ 0.05 60 24
1011.49 - y101+ 0.05 60 32
a 13C and 15N labelled arginine (R) or lysine (K). Underlined product ions represent the quantifier ions.
 


